The steatohepatitic variant of hepatocellular carcinoma and its association with underlying steatohepatitis

Human Pathology

Volumn 43, Issue 5, 2012, Pages 737-746

  Salomao, Marcela ^a   Remotti, Helen ^a   Vaughan, Roger ^b   Siegel, Abby B ^a   Lefkowitch, Jay H ^a   Moreira, Roger Klein ^a  

^a Columbia University College of Physicians and Surgeons ^*  (United States)

^b Columbia University ^*  (United States)

Author keywords

Hepatocellular carcinoma; Metabolic syndrome; NAFLD; NASH; Steatohepatitis

Indexed keywords

CYTOKERATIN 18; CYTOKERATIN 8;

ADULT; ALCOHOL LIVER DISEASE; ARTICLE; CANCER SURGERY; CANCER SURVIVAL; CLINICAL FEATURE; EXPLANT; FATTY LIVER; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; METABOLIC SYNDROME X; NONALCOHOLIC FATTY LIVER; PHENOTYPE; RISK FACTOR; STEATOHEPATITIC HEPATOCELLULAR CARCINOMA; STELLATE CELL;

ADULT; AGED; CARCINOMA, HEPATOCELLULAR; FATTY LIVER; FEMALE; HUMANS; LIVER; LIVER NEOPLASMS; MALE; MIDDLE AGED;

EID: 84859888123     PISSN: 00468177     EISSN: 15328392     Source Type: Journal    
DOI: 10.1016/j.humpath.2011.07.005     Document Type: Article

References (39)

1. Mann CD, Neal CP, Garcea G, et al. Prognostic molecular markers in hepatocellular carcinoma: a systematic review. Eur J Cancer 2007;43:979-92. (Pubitemid 46483030)
2. Gomaa AI, Khan SA, Toledano MB, Waked I, Taylor-Robinson SD. Hepatocellular carcinoma: epidemiology, risk factors and pathogenesis. World J Gastroenterol 2008;14:4300-8.
3. Bosch FX, Ribes J, Diaz M, Cleries R. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:S5-16.
4. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999;340:745-50. (Pubitemid 29114292)
5. Bugianesi E, Leone N, Vanni E, et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002;123:134-40. (Pubitemid 34747534)
6. Siegel AB, Zhu AX. Metabolic syndrome and hepatocellular carcinoma: two growing epidemics with a potential link. Cancer 2009;115:5651-61.
7. Guzman G, Brunt EM, Petrovic LM, Chejfec G, Layden TJ, Cotler SJ. Does nonalcoholic fatty liver disease predispose patients to hepatocellular carcinoma in the absence of cirrhosis? Arch Pathol Lab Med 2008;132:1761-6.
8. Takuma Y, Nouso K. Nonalcoholic steatohepatitis-associated hepatocellular carcinoma: our case series and literature review. World J Gastroenterol 2010;16:1436-41.
9. Caldwell SH, Crespo DM, Kang HS, Al-Osaimi AM. Obesity and hepatocellular carcinoma. Gastroenterology 2004;127:S97-103.
10. Oh SW, Yoon YS, Shin SA. Effects of excess weight on cancer incidences depending on cancer sites and histologic findings among men: Korea National Health Insurance Corporation Study. J Clin Oncol 2005;23:4742-54. (Pubitemid 46224078)
11. Adami HO, Chow WH, Nyren O, et al. Excess risk of primary liver cancer in patients with diabetes mellitus. J Natl Cancer Inst 1996;88: 1472-7. (Pubitemid 26340049)
12. El-Serag HB, Tran T, Everhart JE. Diabetes increases the risk of chronic liver disease and hepatocellular carcinoma. Gastroenterology 2004;126:460-8. (Pubitemid 38182303)
13. Charlton M. Cirrhosis and liver failure in nonalcoholic fatty liver disease: molehill or mountain? Hepatology 2008;47:1431-3. (Pubitemid 351702725)
14. Charlton M. Nonalcoholic fatty liver disease: a review of current understanding and future impact. Clin Gastroenterol Hepatol 2004;2: 1048-58. (Pubitemid 40037633)
15. Koehler E, Watt K, Charlton M. Fatty liver and liver transplantation. Clin Liver Dis 2009;13:621-30.
16. Nzeako UC, Goodman ZD, Ishak KG. Hepatocellular carcinoma in cirrhotic and noncirrhotic livers. A clinico-histopathologic study of 804 North American patients. Am J Clin Pathol 1996;105:65-75.
17. Torbenson M. Review of the clinicopathologic features of fibrolamellar carcinoma. Adv Anat Pathol 2007;14:217-23. (Pubitemid 46659192)
18. Salomao MA, Yu WM, Brown RS, Emond JC, Lefkowitch JH. steatohepatitic hepatocellular carcinoma (SH-HCC): a distinctive histological variant of HCC in hepatitis C virus-related cirrhosis with associated NAFLD/NASH. Am J Surg Pathol 2010;34: 1630-6.
19. Edmondson HA, Steiner PE. Primary carcinoma of the liver: a study of 100 cases among 48,900 necropsies. Cancer 1954;7:462-503.
20. Edge SE, Byrd DR, Compton CC, et al. AJCC cancer staging manual. 7th ed. New York (NY): Springer; 2009.
21. Brunt EM. Nonalcoholic steatohepatitis: definition and pathology. Semin Liver Dis 2001;21:3-16. (Pubitemid 32240482)
22. Alberti KG, Zimmet P, Shaw J. Metabolic syndrome - a new worldwide definition. A consensus statement from the International Diabetes Federation. Diabet Med 2006;23:469-80.
23. Balkau B, Charles MA. Comment on the provisional report from the WHO consultation. European Group for the Study of Insulin Resistance (EGIR). Diabet Med 1999;16:442-3.
24. Executive summary of the third report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA 2001;285:2486-97.
25. Marrero JA, Fontana RJ, Su GL, Conjeevaram HS, Emick DM, Lok AS. NAFLD may be a common underlying liver disease in patients with hepatocellular carcinoma in the United States. Hepatology 2002;36:1349-54.
26. Ratziu V, Bonyhay L, Di Martino V, et al. Survival, liver failure, and hepatocellular carcinoma in obesity-related cryptogenic cirrhosis. Hepatology 2002;35:1485-93. (Pubitemid 34966903)
27. Pouliot MC, Despres JP, Lemieux S, et al. Waist circumference and abdominal sagittal diameter: best simple anthropometric indexes of abdominal visceral adipose tissue accumulation and related cardiovascular risk in men and women. Am J Cardiol 1994;73:460-8. (Pubitemid 24096208)
28. Lew EA, Garfinkel L. Variations in mortality by weight among 750,000 men and women. J Chronic Dis 1979;32:563-76. (Pubitemid 9256615)
29. Wolk A, Gridley G, Svensson M, et al. A prospective study of obesity and cancer risk (Sweden). Cancer Causes Control 2001;12:13-21. (Pubitemid 32125897)
30. Calle EE, Rodriguez C, Walker-Thurmond K, Thun MJ. Overweight, obesity, and mortality from cancer in a prospectively studied cohort of U.S. adults. N Engl J Med 2003;348:1625-38. (Pubitemid 36459468)
31. Moller H, Mellemgaard A, Lindvig K, Olsen JH. Obesity and cancer risk: a Danish record-linkage study. Eur J Cancer 1994;30A:344-50. (Pubitemid 24152476)
32. Wideroff L, Gridley G, Mellemkjaer L, et al. Cancer incidence in a population-based cohort of patients hospitalized with diabetes mellitus in Denmark. J Natl Cancer Inst 1997;89:1360-5. (Pubitemid 27418027)
33. Lagiou P, Kuper H, Stuver SO, Tzonou A, Trichopoulos D, Adami HO. Role of diabetes mellitus in the etiology of hepatocellular carcinoma. J Natl Cancer Inst 2000;92:1096-9. (Pubitemid 30616486)
34. Lackner C, Gogg-Kamerer M, Zatloukal K, Stumptner C, Brunt EM, Denk H. Ballooned hepatocytes in steatohepatitis: the value of keratin immunohistochemistry for diagnosis. J Hepatol 2008;48:821-8.
35. Caldwell S, Ikura Y, Dias D, et al. Hepatocellular ballooning in NASH. J Hepatol 2010;53:719-23.
36. Strnad P, Zatloukal K, Stumptner C, Kulaksiz H, Denk H. Mallory-Denk-bodies: lessons from keratin-containing hepatic inclusion bodies. Biochim Biophys Acta 2008;1782:764-74.
37. Strnad P, Stumptner C, Zatloukal K, Denk H. Intermediate filament cytoskeleton of the liver in health and disease. Histochem Cell Biol 2008;129:735-49.
38. Washington K, Wright K, Shyr Y, Hunter EB, Olson S, Raiford DS. Hepatic stellate cell activation in nonalcoholic steatohepatitis and fatty liver. HUM PATHOL 2000;31:822-8. (Pubitemid 30480453)
39. Reeves HL, Burt AD, Wood S, Day CP. Hepatic stellate cell activation occurs in the absence of hepatitis in alcoholic liver disease and correlates with the severity of steatosis. J Hepatol 1996;25:677-83. (Pubitemid 26373885)